升清化浊方联合抗病毒方案治疗慢性丙型肝炎临床观察

Clinical Observation on ShengQing HuaZhuo Prescriptions Combined with Anti-viral Scheme in Treating Chronic Hepatitis C

目的:观察升清化浊方联合聚乙二醇干扰素α-2a、利巴韦林抗病毒方案治疗慢性丙型肝炎的临床疗效及对白细胞的影响。方法:将慢性丙型肝炎患者60例按照随机数字表法分为治疗组和对照组各30例,对照组采用聚乙二醇干扰素α-2a皮下注射和利巴韦林口服常规抗病毒治疗,必要时间断使用重组人粒细胞刺激因子,治疗组在对照组治疗的基础上联合升清化浊方治疗,疗程为48周,观察2组治疗前后肝功能及HCV-RNA、白细胞等变化情况。结果:2组快速病毒学应答(RVR)、早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)、持续病毒学应答(SVR)比较差异无统计学意义(P>0.05);与治疗前比较,2组ALT、AST治疗后差异均有统计学意义(P<0.05),治疗组ALT、AST改善优于对照组,差异具有统计学意义(P<0.05)。白细胞、中性粒细胞数减低的发生率低于对照组,其差异有统计学意义(P<0.05)。结论:升清化浊方联合聚乙二醇干扰素α-2a及利巴韦林抗病毒方案治疗慢性丙型肝炎能够促进患者肝功能的改善,降低干扰素所致粒细胞减低的发生率。

Objective： To observe clinical effects of ShengQing HuaZhuo prescription jointed with peginterferon α-2a and ribavifin in treating chronic hepatitis C and their influences on white blood cells. Methods： Sixty patients were allocated to the treatment group and the control group according to random number table method, the control group adopted subcutaneous injection of peginterferon α-2a and oral administration of ribavirin, when necessary, they used recombinant human granulocyte colony-stimulating factor on and off, the treatment group took ShengQing HuaZhuo prescription orally based on the treatment the control group accepted, the course of the treatment was 48 weeks, liver function, the changes of HCV-RNA, white blood cells of both groups were observed before and after treating. Results： The difference had no statistical meaning in the comparisons of RVR, EVR, ETVR and SVR be- tween both groups （P〉0.05）, the difference had statistical meaning in the comparions of ALT and AST between both groups after treating compared with before treating （P〈0.05）, the treatment group was superior to the control group in the improvements of ALT and AST, and the difference had statistical rnenaing （P〈0.05）. The treatment group was lower than the control group notably in the incidences of white blood cells and neutrophile granulocyte number decrease significantly, and the difference had statistical meaning （P 〈0.05）. Conclusion： ShengQing HuaZhuo prescription jointed with peginterferon α-2a and ribavirin in treating chronic hepatitis could improve liver function, and it could decrease the incidences ofgranulocyte decrease caused by interferon.